Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | BCHE | P06276 | 3/20 | 0.60 |
| ▸ | BACE1 | P56817 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | CCR6 | P51684 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327650 | 0.84 | DRD2 (0.69) | ACHEBCHEBACE1SIGMAR1CCR6 | |
| SCHEMBL19086828 | 0.84 | ACHE (0.59) | ACHEBCHEBACE1SIGMAR1HRH3 | |
| SCHEMBL2418918 | 0.82 | CCR6 (0.51) | ACHECCR6DRD2 | |
| SCHEMBL4687045 | 0.81 | ACHE (0.59) | ACHEBCHEBACE1MAPK1HRH3 | |
| SCHEMBL4218644 | 0.81 | ACHE (0.58) | ACHEBCHEBACE1SIGMAR1HRH3 | |
| SCHEMBL2420441 | 0.80 | SSTR5 (0.61) | CCR6DRD2 | |
| SCHEMBL2418270 | 0.80 | SSTR5 (0.56) | CCR6DRD2 | |
| SCHEMBL4227761 | 0.80 | ACHE (0.57) | ACHEBCHEBACE1SIGMAR1HRH3 | |
| SCHEMBL2419193 | 0.79 | SSTR5 (0.51) | CCR6 | |
| SCHEMBL15739645 | 0.79 | CCR6 (0.61) | CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137368-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-03 | — | — | US | claimed |
| CN-101663291-A | Pyridine derivate as the dopamine 2 receptor antagonists of fast dissociating | JANSSEN PHARMACEUTICA NV | 2010-03-03 | — | — | CN | claimed |
| EP-2148872-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | claimed |
| WO-2008128994-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | claimed |
| US-20100137368-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137368-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137368-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-03 | — | — | US | disclosed |
| CN-101663291-A | Pyridine derivate as the dopamine 2 receptor antagonists of fast dissociating | JANSSEN PHARMACEUTICA NV | 2010-03-03 | — | — | CN | disclosed |
| EP-2148872-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128994-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137368-A1 | PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | ACHE 214/4885BCHE 1607/4885BACE1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.